{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T15:10:09Z","timestamp":1793632209536,"version":"4.5.1"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e1 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","award":["E-26\/204.521\/2021"],"award-info":[{"award-number":["E-26\/204.521\/2021"]}],"id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["88887.3115972018-00"],"award-info":[{"award-number":["88887.3115972018-00"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["001"],"award-info":[{"award-number":["001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>A maternal vaccine to protect newborns against invasive <jats:italic>Streptococcus agalactiae<\/jats:italic> infection is a developing medical need. The vaccine should be offered during the third trimester of pregnancy and induce strong immune responses and placental transfer of protective antibodies. Polysaccharide vaccines against <jats:italic>S. agalactiae<\/jats:italic> conjugated to protein carriers are in advanced stages of development. Additionally, protein-based vaccines are also in development, showing great promise as they can provide protection regardless of serotype. Furthermore, safety concerns regarding a new vaccine are the main barriers identified. Here, we present vaccines in development and identified safety, cost, and efficacy concerns, especially in high-need, low-income countries.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1430901","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T05:07:47Z","timestamp":1718341667000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":39,"title":["Vaccines for Streptococcus agalactiae: current status and future perspectives"],"prefix":"10.3389","volume":"15","author":[{"given":"Jo\u00e3o Matheus Sobral","family":"Pena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamella Silva","family":"Lannes-Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prescilla Emy","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix653","article-title":"Group B streptococcal disease worldwide for pregnant women, stillbirths, and children: why, what, and how to undertake estimates","volume":"65","author":"Lawn","year":"2017","journal-title":"Clin Infect Dis"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0000000000001223","article-title":"20 million pregnant women with group B streptococcus carriage: consequences, challenges, and opportunities for prevention","volume":"35","author":"Paul","year":"2023","journal-title":"Curr Opin Pediatr"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123014","article-title":"Burden of invasive group B Streptococcus disease and early neurological sequelae in South African infants","volume":"10","author":"Dangor","year":"2015","journal-title":"PloS One"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2022.07.051","article-title":"Group B Streptococcus and the risk of perinatal morbidity and mortality following term labor","volume":"228","author":"Stephens","year":"2023","journal-title":"Am J Obstet Gynecol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2535","article-title":"A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design","volume":"17","author":"Avci","year":"2011","journal-title":"Nat Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz737","article-title":"Safety and immunogenicity of a second dose of an investigational maternal trivalent group B streptococcus vaccine in nonpregnant women 4\u20136 years after a first dose: results from a phase 2 trial","volume":"70","author":"Leroux-Roels","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix666","article-title":"Antibody kinetics and response to routine vaccinations in infants born to women who received an investigational trivalent group B streptococcus polysaccharide CRM197-conjugate vaccine during pregnancy","volume":"65","author":"Madhi","year":"2017","journal-title":"Clin Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1473\u20133099(20)30478\u20133","article-title":"Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1\/2, randomized, placebo-controlled, observer-blinded, dose-escalation trial","volume":"21","author":"Absalon","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz062","article-title":"A novel hexavalent capsular polysaccharide conjugate vaccine (GBS6) for the prevention of neonatal group B streptococcal infections by maternal immunization","volume":"220","author":"Buurman","year":"2019","journal-title":"J Infect Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis605","article-title":"Capsular switching in group B Streptococcus CC17 hypervirulent clone: a future challenge for polysaccharide vaccine development","volume":"206","author":"Bellais","year":"2012","journal-title":"J Infect Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/bdr2.2173","article-title":"Preclinical development of a novel Group B Streptococcus (GBS) vaccine candidate for maternal immunization based upon the alpha-like protein family of GBS surface proteins (Alp)","volume":"115","author":"Banks","year":"2023","journal-title":"Birth Defects Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.106261","article-title":"Safety and immunogenicity of the group B streptococcus vaccine AlpN in a placebo-controlled double-blind phase 1 trial","volume":"26","author":"Gonzalez-Miro","year":"2023","journal-title":"iScience"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.513358","article-title":"Characterization of fibrinogen binding by glycoproteins Srr1 and Srr2 of Streptococcus agalactiae","volume":"288","author":"Seo","year":"2013","journal-title":"J Biol Chem"},{"key":"B14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/infdis\/jix565","article-title":"et al, vaccination with a latch peptide provides serotype-independent protection against group B streptococcus infection in mice","volume":"217","author":"Lin","year":"2017","journal-title":"J Infect Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1086\/513981","article-title":"A role for C5 and C5a-ase in the acute neutrophil response to Group B Streptococcal infections","volume":"175","author":"Bohnsack","year":"1997","journal-title":"J Infect Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2011.06.024","article-title":"Efficacy of polymeric encapsulated C5a peptidase based group B streptococcus vaccines in a murine model","volume":"205","author":"Santillan","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1086\/595564","article-title":"Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm","volume":"199","author":"Margarit","year":"2009","journal-title":"J Infect Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.csbj.2015.11.001","article-title":"Self-assembling protein nanoparticles in the design of vaccines","volume":"14","author":"L\u00f3pez-Sagaseta","year":"2016","journal-title":"Comput Struct Biotechnol J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41541\u2013023-00744\u20135","article-title":"Proof of concept for a single-dose Group B Streptococcus vaccine based on capsular polysaccharide conjugated to Q\u03b2 virus-like particles","volume":"8","author":"Carboni","year":"2023","journal-title":"NPJ Vaccines"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix658","article-title":"Maternal colonization with group B streptococcus and serotype distribution worldwide: systematic review and meta-analyses","volume":"65","author":"Russell","year":"2017","journal-title":"Clin Infect Dis"},{"key":"B21","unstructured":"WHO preferred product characteristics for Group B streptococcus vaccines. Geneva: World Health Organization2017"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1086\/315285","article-title":"Maternal antibody transfer in baboons and mice vaccinated with a group B streptococcal polysaccharide conjugate","volume":"181","author":"Paoletti","year":"2000","journal-title":"J Infect Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1186\/1471\u20132288-13\u201329","article-title":"A threshold method for immunological correlates of protection","volume":"13","author":"Chen","year":"2013","journal-title":"BMC Med Res Methodol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20136736(16)30394\u20134","article-title":"Mind the gap: jumping from vaccine licensure to routine use","volume":"387","author":"O\u2019Brien","year":"2016","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix664","article-title":"Estimates of the burden of group B streptococcal disease worldwide for pregnant women, stillbirths, and children","volume":"65","author":"Seale","year":"2017","journal-title":"Clin Infect Dis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1016\/S0140-6736(13)61682-7","article-title":"Use of vaccines as probes to define disease burden","volume":"383","author":"Feikin","year":"2014","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.1c00415","article-title":"Development and immunogenicity of a prototype multivalent group B streptococcus bioconjugate vaccine","volume":"7","author":"Duke","year":"2021","journal-title":"ACS Infect Dis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9111338","article-title":"Pneumococcal vaccines: past findings, present work, and future strategies","volume":"9","author":"Oliveira","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa537","article-title":"Hib Vaccines: Their Impact on Haemophilus influenzae Type b Disease","volume":"224","author":"Gilsdorf","year":"2021","journal-title":"J Infect Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.04.039","article-title":"The role of immune correlates of protection on the pathway to licensure, policy decision and use of group B Streptococcus vaccines for maternal immunization: considerations from World Health Organization consultations","volume":"37","author":"Vekemans","year":"2019","journal-title":"Vaccine"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy838","article-title":"A phase 2, randomized, control trial of group B streptococcus (GBS) type III capsular polysaccharide-tetanus toxoid (GBS III-TT) vaccine to prevent vaginal colonization with GBS III","volume":"68","author":"Hillier","year":"2019","journal-title":"Clin Infect Dis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw377","article-title":"The protective value of maternal group B streptococcus antibodies: quantitative and functional analysis of naturally acquired responses to capsular polysaccharides and pilus proteins in European maternal sera","volume":"63","author":"Fabbrini","year":"2016","journal-title":"Clin Infect Dis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.01.062","article-title":"Cost-effectiveness of a potential group B streptococcal vaccine program for pregnant women in South Africa","volume":"32","author":"Kim","year":"2014","journal-title":"Vaccine"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100511","article-title":"A group B Streptococcus alpha-like protein subunit vaccine induces functionally active antibodies in humans targeting homotypic and heterotypic strains","volume":"3","author":"Pawlowski","year":"2022","journal-title":"Cell Rep Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms10122483","article-title":"Group B streptococcus: virulence factors and pathogenic mechanism","volume":"10","author":"Liu","year":"2022","journal-title":"Microorganisms"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2017.62","article-title":"The regulation of gut mucosal IgA Bcell responses: recent developments","volume":"10","author":"Lycke","year":"2017","journal-title":"Mucosal Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.5b00247","article-title":"Anti-group B streptococcus glycan-conjugate vaccines using pilus protein GBS80 as carrier and antigen: comparing lysine and tyrosine-directed conjugation","volume":"10","author":"Nilo","year":"2015","journal-title":"ACS Chem Biol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107380","article-title":"Immune responses against group B Streptococcus monovalent and pentavalent capsular polysaccharide tetanus toxoid conjugate vaccines in Balb\/c mice","volume":"26","author":"Dhar","year":"2023","journal-title":"iScience"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.02.071","article-title":"Potential cost-effectiveness of a maternal Group B streptococcal vaccine in The Gambia","volume":"38","author":"Ahmed","year":"2020","journal-title":"Vaccine"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.04.024","article-title":"Vaccine value profile for Group B streptococcus","author":"Trotter","year":"2023","journal-title":"Vaccine"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1819612116","article-title":"On the mechanisms of conjugate vaccines","volume":"116","author":"Rappuoli","year":"2019","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1430901\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T05:07:51Z","timestamp":1718341671000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1430901\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,14]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2024.1430901"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1430901","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,14]]},"article-number":"1430901"}}